A first New Zealand study looked at the role of lutetium-177-P SMA I &T in the progression of metastatic castrate-resistant prostate cancer

Vyas, Madhusudan; Garett, N.; Lim, R.; Fagan, J.

Thumbnail
Share
View fulltext online
Date
2021-11
Citation:
Vyas, M., Garett, N., Lim, R., & Fagan, J. (2021, November). A first New Zealand study looked at the role of lutetium-177-P SMA I &T in the progression of metastatic castrate-resistant prostate cancer. Paper presented at the National ITP Research Symposium 2021, Wellington, New Zealand.
Permanent link to Research Bank record:
https://hdl.handle.net/10652/5590
Abstract
Prostate cancer that has spread beyond the prostate gland and is resistant to castration is a deadly disease that poses a threat to men's health. The current standard of care for metastatic prostate cancer is hormonal manipulation. However, metastatic castration-resistant prostate cancer (mCRPC) remains a significant treatment and management challenge. Recently, the use of lutetium-177 (Lu177) labelled ligands against PSMA was found to be compelling and resulted in an increase in overall patient survival.
Keywords:
New Zealand, cancer patients, prostate cancer, theranostics, radionuclide therapy, Lu-177, Lutetium-177, neuroendocrine tumours (NETs), metastatic castration-resistant prostate cancer (mCRPC), mCRPC
ANZSRC Field of Research:
3211 Oncology and carcinogenesis, 320215 Nuclear medicine
Copyright Holder:
Authors

Copyright Notice:
All rights reserved
Rights:
This digital work is protected by copyright. It may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use. These documents or images may be used for research or private study purposes. Whether they can be used for any other purpose depends upon the Copyright Notice above. You will recognise the author's and publishers rights and give due acknowledgement where appropriate.
Metadata
Show detailed record
This item appears in